CD8A and ovarian cancer: In a sample of 40 ovarian cancer patients, Nielsen et al. [9] demonstrated that CD20+ B cells co-localized with activated CD8+ TILs expressing antigen presentation markers and correlated with increased patient survival compared with CD8+ TILs alone.